We evaluated the Amplicor PCR assay (Roche Molecular Systems, Branchburg, N.J.) for direct detection of Mycobacterium tuberculosis in sputum. A total of 532 specimens from 270 patients were decontaminated and stored at 4 or ؊75؇C until assayed by PCR. This assay used three-step sample preparation, biotinylated primer pairs, AmpErase, and a microtiter format for amplicon capture and detection. Amplicor PCR results were compared with clinical history, culture from a Lowenstein-Jensen slant, and results from the BACTEC TB-460 system. Eighty-seven cultures from 15 patients grew M. tuberculosis; of these, 83 (95%) were positive with the Amplicor PCR test. The false negatives were most likely due to sample variation and inhibitors. Of the 445 specimens from which M. tuberculosis was not isolated, 428 (96%) were negative with the Amplicor PCR test. Of the 17 M. tuberculosis culture-negative, Amplicor-positive specimens, 15 were reclassified as true positives because previous cultures grew M. tuberculosis. Of the 445 specimens which did not grow M. tuberculosis, Mycobacterium spp. other than M. tuberculosis were isolated from 150 specimens. Three of these 150 specimens were Amplicor positive; two were from a patient with a history of tuberculosis, and one specimen gave a false-positive result. We do not feel that this represents cross-reactivity, because repeated Amplicor testing of the isolate gave negative results. The microtiter plate has 96 wells. Allowing for six controls, 90 decontaminated specimens can be tested by one technologist in 7.5 h. This PCR assay took 7.5 h to complete and is a sensitive and specific, rapid method for the direct detection of M. tuberculosis from sputum.

Two commercial kit systems, the API Staph-Ident system (Analytab Products, Inc., Plainview, N.Y.) and the DMS Staph-Trac system (DMS Laboratories, Inc., Flemington, N.J.), were compared with conventional methods for the identification of nine species of coagulase-negative staphylococci. The API Staph-Ident system, a biochemical and chromogenic substrate micromethod, correctly identified 95 of 120 (79.2%) clinical isolates of coagulase-negative staphylococci after 5 h of incubation. The DMS Staph-Trac system, a miniaturized biochemical test system which requires a 24-h incubation period, correctly identified 106 (88.3%) of the same isolates. Both commercial systems were similar in cost and amount of technologist time required to inoculate and read each system. The clinical value of routine species identification of coagulasenegative staphylococci has not yet been established. The decision by clinical laboratories of whether to adopt this practice will be greatly facilitated by the availability of commercial kit systems which are both rapid and accurate.

No abstract

No abstract

To determine the reliability of the Baxter MicroScan Yeast Identification Panel, processed by the Walkaway-96, and the Vitek Yeast Biochemical Card, 150 clinical yeast isolates (30 Candida albicans, 67 Candida species, not albicans, 26 Torulopsis glabrata, 13 Cryptococcus neoformans, 4 Saccharomyces cerevisiae, 6 Trichosporon beigelii, 3 Rhodotorula species, and 1 Geotrichum species) were tested on both systems. Results were compared with those obtained by the API 20C and the appearance of yeast cells on cornmeal Tween-80 agar. After inoculation of each system, results were available in 4 hours with MicroScan panels, 24-48 hours with Vitek cards, and 72 hours with the API 20C strips. On initial testing, 101 (67%) and 128 (85%) isolates, respectively, were correctly identified by MicroScan and Vitek. After repeat testing, the number of correctly identified isolates increased to 123 (82%) by MicroScan and to 142 (95%) by Vitek. Yeasts most commonly misidentified were Candida tropicalis, T glabrata, and Candida parapsilosis by MicroScan and C tropicalis and T glabrata by Vitek.